MRL Ventures

MRL Ventures Fund, LLC is Merck's independent early-stage bio-therapeutics venture capital fund. The firm has been in operation since 2004, in Cambridge, Massachusetts, United States.

The firm is interested in investing in seed and early-stage therapeutics companies, and breakthrough sciences that are created to deliver new medicines that improve human health. MRL Ventures Fund is interested in investing during Series A through C rounds in companies such as Imgo BioSciences, Entrada Therapeutics, Rheostat Therapeutics, and Kymera Therapeutics.

MRL Ventures Fund, LLC is Merck's independent early-stage bio-therapeutics venture capital fund. The firm has been in operation since 2004, in Cambridge, Massachusetts, United States.

The firm is interested in investing in seed and early-stage therapeutics companies, and breakthrough sciences that are created to deliver new medicines that improve human health. MRL Ventures Fund is interested in investing during Series A through C rounds in companies such as Imgo BioSciences, Entrada Therapeutics, Rheostat Therapeutics, and Kymera Therapeutics.

MRLVMRL Ventures is a venture capital fund that invests in early-stage therapeutic companies that transform patient care globally. The firm is based in Cambridge, Massachusetts, United States.

MRLV Ventures is a venture capital fund that invests in early-stage therapeutic companies that transform patient care globally. The firm is based in Cambridge, MassachusettsCambridge, Massachusetts, United States.

MRLV Ventures is a venture capital fund that invests in early-stage therapeutic companies that transform patient care globally. The firm is based in Cambridge, Massachusetts, United States.

The firm looks for companies that are developing transformative medicines which have the potential to improve patient livelihood. The firm does not ask for product or technology rights as a condition of investment. Medical devices, diagnostic platforms, and digital health are not the focus of MRLV, only patient care.